Although a previous study reported worse outcomes in patients with early (stages II–III) PIK3CA-mutant CRC (Kato et al, 2007), the aggregate data do not currently suggest that KRAS- or PIK3CA-mutant tumours have distinctive clinical profiles or differential response to currently approved chemotherapy. This evidence concerns the gene KRAS and neoplasm.